Navigation Links
Cocaine: How addiction develops
Date:8/21/2008

ists performed standardized tests to measure addictive behavior in the animals. At first sight, both the genetically modified and the control animals displayed the usual behavior under the influence of cocaine. Forced to increase their agility, the lab animals covered significantly greater running distances and preferentially frequented those places where they had been conditioned to be regularly administered the drug.

If normal mice do not find drugs at the familiar places over a longer period of time, their addictive behavior and preference for the cocaine-associated places subside. However, this is not true for animals whose receptor subunit GluR1 has been switched off: These mice invariably frequent the places where they expect to find the drug, i.e., their addictive behavior persists.

Mice whose NR1 protein has been switched off have surprised scientists with a different conspicuous behavior. If control animals withdrawn from cocaine are readministered the drug after some time, addictive behavior and drug seeking are reactivated. In contrast, NR1 deficient animals proved to be resistant to relapsing into the addiction.

"It is fascinating to observe how individual proteins can determine addictive behavioral patterns," says Gnther Schtz, and his colleague Rainer Spanagel adds: "In addition, our results open up whole new prospects for treating addiction. Thus, blocking the NR1 receptor might protect from relapsing into addiction. Selective activation of GluR1 would even contribute to 'extinguishing' the addiction."


'/>"/>

Contact: Dr. Sibylle Kohlstdt
s.kohlstaedt@dkfz.de
Helmholtz Association of German Research Centres
Source:Eurekalert

Page: 1 2

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. New genetic research into nicotine addiction shows promise for personalized treatment
3. Can plant-based ethanol save us from our fossil fuel addiction?
4. Cognitive, genetic clues identified in imaging study of alcohol addiction
5. Hungry mothers risk addiction in their adult children
6. Corals addiction to junk food
7. Erasing drug-associated memories may stop drug addiction relapses
8. Large-scale investment catapults CAMHs mental illness and addiction research forward
9. How schizophrenia develops: Major clues discovered
10. MIT develops tractor beam for cells, more
11. Team of scientists develops non-invasive method to track nerve-cell development in live human brain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... critical security-authentication needs, today announced the beginning of shipments ... solution. The company, based in ... the three-day Connect:ID Expo, which began here today at ... said version 2.0 of its SDK boosts the accuracy ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... fossilized tracksite in southern Africa shows how early dinosaurs ... slippery and sloping terrain. Differences in how early dinosaurs ... of the group. The research, conducted by researchers ... Aires, and the Iziko South African Museum in Cape ...
... risk of allergy. Cathleen Muche-Borowski and her coauthors present ... current issue of Deutsches rzteblatt International (Dtsch ... becoming increasingly common in Western industrialized countries. As there ... hay fever, or atopic eczema, the prevention of these ...
... Va. A five-year-old Virginia Tech outreach program, ... doing research and providing results that scientists can ... Partnership Award from the National Center for Research ... of Health. The Fralin Life Science Institute,s Partnership ...
Cached Biology News:Trackway analysis shows how dinosaurs coped with slippery slopes 2Trackway analysis shows how dinosaurs coped with slippery slopes 3NIH funds new phase of high school-university research partnership 2NIH funds new phase of high school-university research partnership 3
(Date:5/1/2015)... 2015 Pfenex Inc. (NYSE MKT: PFNX), ... of biosimilar therapeutics including high value and difficult ... quarter 2015 financial results will be released on ... market. At 8:30 am Eastern Time, Pfenex management will ... results and provide a business update. A press release ...
(Date:5/1/2015)... 1, 2015 According to ... Product (Equipment, Consumables), by Type (Monoclonal, Polyclonal), by ... Research Institutes) - Analysis & Global Forecast to ... global Antibody Production Market for the forecast period ... to reach $2.572 Billion by 2019 from $1.425 ...
(Date:4/30/2015)... Francisco, CA (PRWEB) April 30, 2015 Cytokinetics, ... the first quarter of 2015 were $4.4 million, compared to ... net loss for the first quarter was $8.9 million, or ... a net loss for the same period in 2014, of ... As of March 31, 2015, cash, cash equivalents and investments ...
(Date:4/30/2015)... 30, 2015 Biodata, producer of ... integrated protocols and specimen management systems, and ChemAxon, ... consulting services for life science research, announce their ... newest feature: chemical structure and reaction support. Already ... biologists, bio-chemists, and more, the integration of ChemAxon's ...
Breaking Biology Technology:Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2
... Agence de Medecine,Preventive (AMP) announced today the appointment ... SIVAC (Supporting Independent Immunization and,Vaccine Advisory Committees) initiative. ... national immunization technical advisory groups in six,resource poor ... committees will help,national health authorities to set up ...
... 12 Synvista Therapeutics, Inc. (NYSE Alternext ... BENEFICIAL study, a Phase 2 double-blind, placebo-controlled, randomized trial of ... the effect of alagebrium on exercise tolerance in patients with ... enrollment of its BREAK ( B eginning a R ...
... ANA, Calif., Jan. 12 ,Abbott ( NYSE: ABT ) and ... a definitive agreement for Abbott to acquire AMO for $22 ... $2.8 billion, inclusive,of estimated net debt at the time of ... leader in ophthalmic care, comprised of three segments: cataract,surgery, laser ...
Cached Biology Technology:French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 2French Agency AMP Appoints Dr Kamel Senouci as Director of SIVAC Initiative (Supporting Independent Immunization and Vaccine Advisory Committees) 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 2Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 3Synvista Therapeutics Announces Progress in Phase 2 Clinical Trial Program for Alagebrium 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 2Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 3Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 4Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 5Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 6Abbott Expands Its Growing Medical Device Business With Acquisition of Advanced Medical Optics (AMO) 7